Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ARTimmune

Financiado

Cerrado

Programmable ARTificial immune systems to fight cancer

Immunotherapy has entered centre stage as a novel treatment modality for cancer. Notwithstanding this major step forward, toxicity and immunosuppression remain major obstacles, and illustrate the pressing need for more powerful an... ver más

31/07/2025

RADBOUDUMC

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-06-05

ERC-2018-ADG: ERC Advanced Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

RADBOUDUMC

2.50M€ | Lider

TORCH CUTTING TECHNOLOGY SL

379.51K€ | Participante

STICHTING RADBOUD UNIVERSITE...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TROJAN-Cell Developing novel single-cell technologies to model and pertu... 3M€ Cerrado

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

IMMUNO-TEX Overcoming resistance to immunotherapy: Immunostimulatory tu... 2M€ Cerrado

SPLITVAC Harnessing the innate and adaptive immune system with target... 173K€ Cerrado

SupraCODE Spatial control of antigen-encoded supramolecular copolymers... Cerrado

Duración del proyecto: 73 meses Fecha Inicio: 2019-06-05
Fecha Fin: 2025-07-31

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immunotherapy has entered centre stage as a novel treatment modality for cancer. Notwithstanding this major step forward, toxicity and immunosuppression remain major obstacles, and illustrate the pressing need for more powerful and specific immunotherapies against cancer. To overcome these roadblocks, in ARTimmune, I propose to follow a radically different approach by developing local rather than systemic immunotherapies. Taking advantage of the architecture of a lymph node (LN), I aim to design fully synthetic immune niches to locally instruct immune cell function. I hypothesize that programmable synthetic immune niches, when injected next to a tumour, will act as local powerhouses to generate bursts of cytotoxic T cells for tumour destruction, without toxic side effects. Single cell transcriptomics on LN, obtained from patients that are vaccinated against cancer, will provide unique insight in communication within immune cell clusters and provide a blueprint for the intelligent design of synthetic immune niches. Chemical tools will be used to build branched polymeric structures decorated with immunomodulating molecules to mimic LN architecture. These will be injected, mixed with sponge-like scaffolds to provide porosity needed for immune cell infiltration. Programming of immune cell function will be accomplished by in vivo targeting- and proteolytic activation- of immunomodulators for fine-tuning, and to extend the life span of these local powerhouses. The innovative character of ARTimmune comes from: 1) novel fundamental immunological insight in complex communication within LN cell clusters, 2) a revolutionary new approach in immunotherapy, by the development of 3) injectable- and 4) programmable- synthetic immune niches by state-of-the-art chemical technology. When successful, it will revolutionize cancer immunotherapy, moving from maximal tolerable dose systemic treatment with significant toxicity to local low dose treatment in the direct vicinity of a tumour

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores